Prosecution Insights
Last updated: November 12, 2026
Application No. 18/743,664

MULTIPLE FOLATE FORMULATION AND USE THEREOF

Non-Final OA §103§DOUBLEPATENT
Filed
Jun 14, 2024
Priority
Sep 11, 2012 — continuation of 13/609,985 +1 more
Examiner
OLSON, ANDREA STEFFEL
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Jaymac Pharmaceutical LLC
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
51%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
897 granted / 1434 resolved
+2.6% vs TC avg
Minimal -12% lift
Without
With
+-11.9%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
59 currently pending
Career history
1504
Total Applications
across all art units

Office Action

§103 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Detailed Action This application is a continuation of US application 15/483858, now abandoned, filed April 10, 2017, which is a continuation of US application 13/609985, now abandoned, filed September 11, 2012. Claims 1-16 are pending in this application and examined on the merits herein. Claim Rejections - 35 USC § 103 The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-3, 5-10, 12, 15, and 16 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Hahnlein et al. (US pre-grant publication 2003/0143304, cited in PTO-892) in view of Destaillats et al. (US pre-grant publication 2011/0028434, cited in PTO-1449) Independent claim 1 is directed to a composition of three different forms of folate, specifically pteroylmonoglutamic acid, (folic acid) 5-formyltetrahydrofolic acid, (folinic acid or leucovorin) and 5-methyl-tetrahydrofolic acid, in combination with a phospholipid conjugate containing at least one of a number of unsaturated fatty acids. Hahnlein et al. discloses a composition of folic acid, 5-methyltetrahydrofolic acid, and a dietary or nutrient component. (p. 2 paragraphs 14-18) These compositions are intended to ensure adequate folate supply to subjects suffering from folate deficiency, including those having disorders in folate metabolism, including genetic disorders. (p. 2 paragraph 12) Hahnlein et al. additionally discloses a preferred embodiment in which the composition contains at least one other reduced folate besides 5-methyltetrahydrofolate, including for example 5-formyltetrahydrofolate. (p. 3 paragraph 27) Therefore Hahnlein et al. discloses an embodiment wherein the composition discloses folic acid, 5-methyltetrahydrofolate, and 5-formyltetrahydrofolate. Additionally, even if it were concluded that the reference does not specifically disclose such a combination, it would have been obvious to one of ordinary skill in the art at the time of the invention to make a combination of these three folates given the general disclosure of “other reduced folates” by Hahnlein. Furthermore, while Hahnlein does not specifically disclose including in the composition a phospholipid containing one of the recited fatty acids, Destaillats et al. discloses administering a nutritional composition to a pregnant subject to increase DHA levels in the neonate, providing adequate levels in the brain and retina of the neonate. (p. 1 paragraphs 12-14) These compositions preferably include a fatty acid such as ARA, EPA, or DHA in the form of a phospholipid such as PC. (p. 1 paragraphs 17-19) The phospholipids can be obtained from various animal sources including egg lecithins. (p. 2 paragraph 22) The composition can further include 0.5-1.5 mg vitamin B6 (pyridoxine) and 0.5-2 µg vitamin B12. (pp. 2-3 paragraph 39) Additionally Hahnlein et al. discloses their multiple folate compositions as being useful for administration to pregnant subjects. (p. 5 paragraph 50 – p. 5 paragraph 52) It would therefore have been obvious to one of ordinary skill in the art at the time of the invention to additionally include phospholipids such as egg lecithin containing ARA, EPA, or DHA in the compositions described by Hahnlein et al. Specifically, one of ordinary skill in the art would have seen that “nutritional” components as described by Hahnlein et al. would include any other nutrient reasonably expected to be useful to the subject population consuming the supplement, and would have expected based on Destaillats that the recited phospholipids would be useful for pregnant subjects. Regarding claims 2-4 and 11, Hahnlein et al. discloses that the composition preferably comprises vitamin B6 and/or vitamin B12. (p. 4 paragraph 33) The vitamin B12 is preferably present in an amount of 0.4mg. (p. 4 paragraph 40) Regarding claim 5, Hahnlein discloses doses of 200 or 400 µg of folic acid and 400 or 800 µg 5-methyltetrahydrofolic acid. (p. 4 paragraphs 46-48) Elsewhere higher doses of folates are disclosed including for example 4-8 mg of 5-methyltetrahydrofolic acid. (p. 4 paragraph 37) It would therefore have been obvious to one of ordinary skill in the art at the time of the invention to determine an appropriate dosage for each of the three claimed folates, when all three are present together. Regarding claims 7, 8, 15, and 16, Hahnlein et al. discloses that specific isomers of the folate compounds can be used, including preferably the 6S isomers. (pp. 2-3 paragraphs 25 and 27) For these reasons the invention taken as a whole is prima facie obvious. Claims 3, 13, and 14 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Hahnlein et al. in view of Destaillats et al. as applied to claims 1-12, 15, and 16 above, and further in view of Edwards et al. (US pre-grant publication 2006/0217385, cited in PTO-1449) The disclosures of Hahnlein et al. and Destaillats et al. are discussed above. Hahnlein et al. do not specifically disclose the particular combination of vitamin B12 compounds recited in claims 13 and 14. Edwards et al. discloses a composition for improving the nutritional status of a pregnant subject and child during all stages of pregnancy. (p. 2 paragraph 19) The composition contains one or more folates as well as one or more essential fatty acids. (p. 2 paragraph 20) These compositions are especially beneficial to subjects having a folate deficiency or folate metabolic disorder. (p. 3 paragraph 24) The composition additionally comprises vitamin B₆ such as pyridoxine or derivatives thereof, as well as vitamin B₁₂ including methylcobalamin, deoxyadenosylcobalamin, and combinations thereof in an amount of 20-250ug, which overlaps the range recited in present claims 3, 13, and 14. It would therefore have been obvious to one of ordinary skill in the art at the time of the invention to include methylcobalamin and adenosylcobalamin in the claimed amounts in a composition as described by Hahnlein et al. in view of Destaillats et al. One of ordinary skill in the art would have been motivated to do so because Edwards et al. describes combinations of these two ingredients as being useful for administration to the same subject population along with folates, reduced folates, and essential fatty acids. Therefore the invention taken as a whole is prima facie obvious. Claims 4 and 11 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Hahnlein et al. in view of Destaillats et al. as applied to claims 1-12, 15, and 16 above, and further in view of Freisen et al. (US pre-grant publication 2006/0148763, cited in PTO-1449) The disclosures of Hahnlein et al. and Destaillats et al. are discussed above. Hahnlein et al. do not specifically disclose the particular vitamin B6 compounds recited in claims 4 and 11. Friesen et al. discloses administering vitamin B₆ to a patient to prevent or treat hypertriglyceridemia. (p. 2 paragraph 11) The vitamin B₆ can be in the form of pyridoxal-5'-phosphate. (p. 2 paragraph 13) In a specific embodiment the patient being treated has a hormonal disturbance such as pregnancy. (p. 3 paragraph 57) It would have been obvious to one of ordinary skill in the art at the time of the invention to use pyridoxal-5'-phosphate. as the vitamin B₆ in the prior art composition. One of ordinary skill in the art would have been motivated to do so and would have reasonably expected success because Friesen et al. specifically discloses that pyridoxay-5'-phosphate is one of the forms of vitamin B₆ that can be administered to pregnant subjects. Therefore the invention taken as a whole is prima facie obvious. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-3, 5-10, 12, 15, and 16 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 9, and 11 of U.S. Patent No. 9216199 (Cited in PTO-1449, herein referred to as ‘199) in view of Hahnlein et al. (US pre-grant publication 2003/0143304, cited in PTO-892) Claim 1 of ‘199 claims a composition comprising phosphatidylcholine:DHA, folate, vitamin B6, and vitamin B12. Claim 2 of ‘199 further claims specific amounts for each of these compounds. Claim 9 of ‘199 further describes the folate as comprising multiple folates. While the claims of ‘199 do not specifically require that the “multiple folates” comprise the three specific compounds recited in the present claims, claim 11 describes the composition as specifically being used for providing prenatal and postnatal nutrition for a mother. The disclosure of Hahnlein et al. is as discussed previously under 35 USC 103. It would have been obvious to one of ordinary skill in the art at the time of the invention to use a combination of three different folates among those recited by Hahnlein et al. as the “more than one form of folate” described in the claims of ‘199. One of ordinary skill in the art would have seen the recitation of “more than one form of folate” as suggesting looking to prior art combinations of multiple forms of folate, such as that described by Hahnlein et al. Claims 4 and 11 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 9, and 11 of U.S. Patent No. 9216199 (Cited in PTO-1449, herein referred to as ‘199) in view of Hahnlein et al. (US pre-grant publication 2003/0143304, cited in PTO-892) in view of Freisen et al. (US pre-grant publication 2006/0148763, cited in PTO-1449) The claims of ‘199 and the disclosure of Hahnlein et al. is discussed above. The claims of ‘199 in view of Hahnlein et al. do not specifically disclose the particular vitamin B6 compounds recited in claims 4 and 11. Friesen et al. discloses administering vitamin B₆ to a patient to prevent or treat hypertriglyceridemia. (p. 2 paragraph 11) The vitamin B₆ can be in the form of pyridoxal-5'-phosphate. (p. 2 paragraph 13) In a specific embodiment the patient being treated has a hormonal disturbance such as pregnancy. (p. 3 paragraph 57) It would have been obvious to one of ordinary skill in the art at the time of the invention to use pyridoxal-5'-phosphate. as the vitamin B₆ in the prior art composition. One of ordinary skill in the art would have been motivated to do so and would have reasonably expected success because Friesen et al. specifically discloses that pyridoxay-5'-phosphate is one of the forms of vitamin B₆ that can be administered to pregnant subjects. Claims 3, 13, and 14 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 9, and 11 of U.S. Patent No. 9216199 (Cited in PTO-1449, herein referred to as ‘199) in view of Hahnlein et al. (US pre-grant publication 2003/0143304, cited in PTO-892) in view of Edwards et al. (US pre-grant publication 2006/0217385, cited in PTO-1449) The claims of ‘199 and the disclosure of Hahnlein et al. is discussed above. The claims of ‘1998 in view of Hahnlein et al. do not specifically disclose the particular combination of vitamin B12 compounds recited in claims 13 and 14. Edwards et al. discloses a composition for improving the nutritional status of a pregnant subject and child during all stages of pregnancy. (p. 2 paragraph 19) The composition contains one or more folates as well as one or more essential fatty acids. (p. 2 paragraph 20) These compositions are especially beneficial to subjects having a folate deficiency or folate metabolic disorder. (p. 3 paragraph 24) The composition additionally comprises vitamin B₆ such as pyridoxine or derivatives thereof, as well as vitamin B₁₂ including methylcobalamin, deoxyadenosylcobalamin, and combinations thereof in an amount of 20-250ug, which overlaps the range recited in present claims 3, 13, and 14. It would therefore have been obvious to one of ordinary skill in the art at the time of the invention to include methylcobalamin and adenosylcobalamin in the claimed amounts in a composition as recited in the claims of ‘199 One of ordinary skill in the art would have been motivated to do so because Edwards et al. describes combinations of these two ingredients as being useful for administration to the same subject population along with folates, reduced folates, and essential fatty acids. Conclusion No claims are allowed in this action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREA OLSON whose telephone number is (571)272-9051. The examiner can normally be reached M-F 6am-3:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Y Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDREA OLSON/ Primary Examiner, Art Unit 1693 10/13/2026
Read full office action

Prosecution Timeline

Jun 14, 2024
Application Filed
Oct 15, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788807
PENTAVALENT VACCINE AGAINST NEISSERIA MENINGITIDIS COMPRISING A SYNTHETIC MEN A ANTIGEN
3y 8m to grant Granted Nov 10, 2026
Patent 12790447
METHOD FOR PREPARING ACYLATED CROSSLINKED GLYCOSAMINOGLYCANS
2y 8m to grant Granted Nov 10, 2026
Patent 12780951
METHOD FOR PRODUCING CATIONIZED CELLULOSE AND CATIONIZED CELLULOSE
4y 5m to grant Granted Nov 03, 2026
Patent 12782341
METHOD FOR EXTRACTING AND IDENTIFYING POLYSACCHARIDE FROM COMPLEX SAMPLE
2y 11m to grant Granted Nov 03, 2026
Patent 12773420
CANCER CHEMOTHERAPY SUPPORTING AGENT, FOOD, AND DRUG
4y 8m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
51%
With Interview (-11.9%)
Low
PTA Risk
Based on 1434 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month